HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
Nakaraang pagsara
$2.21
Sakop ng araw
$2.17 - $2.26
Sakop ng taon
$0.97 - $9.79
Market cap
10.62M USD
Average na Volume
545.58K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 1.86M | -16.35% |
Net na kita | -1.77M | 17.87% |
Net profit margin | — | — |
Kita sa bawat share | — | — |
EBITDA | -1.87M | 15.24% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 13.28M | 105.07% |
Kabuuang asset | 13.44M | 96.12% |
Kabuuang sagutin | 1.27M | 1.68% |
Kabuuang equity | 12.17M | — |
Natitirang share | 4.80M | — |
Presyo para makapag-book | 0.87 | — |
Return on assets | -48.81% | — |
Return on capital | -55.41% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -1.77M | 17.87% |
Cash mula sa mga operasyon | -1.28M | 36.60% |
Cash mula sa pag-invest | -2.00K | — |
Cash mula sa financing | 9.17M | 229,425.00% |
Net change in cash | 7.90M | 491.86% |
Malayang cash flow | -678.00K | 43.76% |
Tungkol
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Itinatag
2011
Headquarters
Website
Mga Empleyado
5
